Skip to main content
Erschienen in: Current Atherosclerosis Reports 1/2012

01.02.2012 | Nonstatin Drugs (W Borden, Section Editor)

Lipid Effects of Antihypertensive Medications

verfasst von: Roderick Deano, Matthew Sorrentino

Erschienen in: Current Atherosclerosis Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Thiazide diuretics and beta-blockers are first-line therapies for hypertension unless there are compelling indications for other drug classes. Diuretics and beta-blockers, however, may worsen dyslipidemia and glucose tolerance whereas antihypertensive agents in other drug classes may have neutral or beneficial effects. Initial clinical trials of antihypertensive regimens suggested that blood pressure lowering was the most important aspect of therapy and that the adverse effects on lipids and glucose tolerance did not impact clinical outcomes. Newer trials, however, question this finding and implicate these pleotropic effects as contributing to the results of the trials. Patients with cardiometabolic risk factors may have compelling indications for agents that inhibit the renin-angiotensin-aldosterone system, relegating diuretics and beta-blockers to third-line therapy.
Literatur
1.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRef
2.
Zurück zum Zitat Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000;23:1278–83.PubMedCrossRef Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000;23:1278–83.PubMedCrossRef
3.
Zurück zum Zitat Gress TW, Nieto FJ, Shahar E, et al. Hypertension and anti-hypertensive therapy as risk factors for Type 2 diabetes mellitus. N Engl J Med. 2000;342:905–12.PubMedCrossRef Gress TW, Nieto FJ, Shahar E, et al. Hypertension and anti-hypertensive therapy as risk factors for Type 2 diabetes mellitus. N Engl J Med. 2000;342:905–12.PubMedCrossRef
4.
Zurück zum Zitat Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep. 2006;8:403–8.PubMedCrossRef Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep. 2006;8:403–8.PubMedCrossRef
5.
Zurück zum Zitat Weidmann P, de Courten M, Ferrari P, et al. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol. 1993;22 Suppl 6:S98–105.PubMed Weidmann P, de Courten M, Ferrari P, et al. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol. 1993;22 Suppl 6:S98–105.PubMed
6.
Zurück zum Zitat Lardinois CK, Newman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148:1280–8.PubMedCrossRef Lardinois CK, Newman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148:1280–8.PubMedCrossRef
7.
Zurück zum Zitat Lasser NL, Grandits G, Caggiula AQ, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984;76:52–62.PubMedCrossRef Lasser NL, Grandits G, Caggiula AQ, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984;76:52–62.PubMedCrossRef
8.
Zurück zum Zitat Feher MD, Betteridge DJ. Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy. Cardiovasc Drugs Ther. 1989;3 Suppl 1:333–40.PubMedCrossRef Feher MD, Betteridge DJ. Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy. Cardiovasc Drugs Ther. 1989;3 Suppl 1:333–40.PubMedCrossRef
9.
Zurück zum Zitat Kasiske BL, Ma JZ, Roberto SN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122:133–41.PubMed Kasiske BL, Ma JZ, Roberto SN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122:133–41.PubMed
10.
Zurück zum Zitat Lakshman MR, Reda DJ, Matersib BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med. 1999;159:551–8.PubMedCrossRef Lakshman MR, Reda DJ, Matersib BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med. 1999;159:551–8.PubMedCrossRef
11.
Zurück zum Zitat Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J. 2000;139:174–83.PubMedCrossRef Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J. 2000;139:174–83.PubMedCrossRef
12.
Zurück zum Zitat ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981–97.CrossRef ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981–97.CrossRef
13.
Zurück zum Zitat Stump CS, Hamilton MT, Sowers JR. Effect of anti-hypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006;81:796–806.PubMedCrossRef Stump CS, Hamilton MT, Sowers JR. Effect of anti-hypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006;81:796–806.PubMedCrossRef
14.
Zurück zum Zitat Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J. 1983;106:245–51.PubMedCrossRef Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J. 1983;106:245–51.PubMedCrossRef
15.
Zurück zum Zitat Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203–9.PubMedCrossRef Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203–9.PubMedCrossRef
16.
Zurück zum Zitat Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226–30.PubMedCrossRef Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226–30.PubMedCrossRef
17.
Zurück zum Zitat Sowers J, Bakris G. Antihypertensive therapy and the risk of Type 2 diabetes mellitus. New Engl J Med. 2000;342:969–70.PubMedCrossRef Sowers J, Bakris G. Antihypertensive therapy and the risk of Type 2 diabetes mellitus. New Engl J Med. 2000;342:969–70.PubMedCrossRef
18.
Zurück zum Zitat Goldner MG, Zurkowitz H, Akgren S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. New Engl J Med. 1960;262:405–505.CrossRef Goldner MG, Zurkowitz H, Akgren S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. New Engl J Med. 1960;262:405–505.CrossRef
19.
Zurück zum Zitat Shapiro AP, Benedek TG, Small JL. Effect of thiazides on carbohydrate metabolism in patients with hypertension. New Engl J Med. 1961;265:1028–33.CrossRef Shapiro AP, Benedek TG, Small JL. Effect of thiazides on carbohydrate metabolism in patients with hypertension. New Engl J Med. 1961;265:1028–33.CrossRef
20.
Zurück zum Zitat Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care. 2004;27:247–55.PubMedCrossRef Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care. 2004;27:247–55.PubMedCrossRef
21.
Zurück zum Zitat Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta analysis. Lancet. 2007;369:201–7.PubMedCrossRef Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta analysis. Lancet. 2007;369:201–7.PubMedCrossRef
22.
Zurück zum Zitat SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRef SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRef
23.
Zurück zum Zitat Papadopoulos DP, Papademetriou V. Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. Clin Exp Hypertens. 2007;29:503–16.PubMedCrossRef Papadopoulos DP, Papademetriou V. Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. Clin Exp Hypertens. 2007;29:503–16.PubMedCrossRef
24.
Zurück zum Zitat Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep. 2000;2:370–7.PubMedCrossRef Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep. 2000;2:370–7.PubMedCrossRef
25.
Zurück zum Zitat Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J. 1992;13(suppl G):5–9.PubMed Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J. 1992;13(suppl G):5–9.PubMed
26.
Zurück zum Zitat Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32:106–11.PubMedCrossRef Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32:106–11.PubMedCrossRef
27.
Zurück zum Zitat • Chatterjee R, Yeh HC, Shafi T, et al Serum and dietary potassium and risk of incident type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2010;170:1745–51. This observational study suggests a link between serum potassium levels and the risk of incident diabetes mellitus and may help explain the higher incidence of diabetes in individuals treated with thiazide diuretics. PubMedCrossRef • Chatterjee R, Yeh HC, Shafi T, et al Serum and dietary potassium and risk of incident type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2010;170:1745–51. This observational study suggests a link between serum potassium levels and the risk of incident diabetes mellitus and may help explain the higher incidence of diabetes in individuals treated with thiazide diuretics. PubMedCrossRef
28.
Zurück zum Zitat Shafi T, Appel LJ, Miller ER, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022–9.PubMedCrossRef Shafi T, Appel LJ, Miller ER, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022–9.PubMedCrossRef
29.
Zurück zum Zitat Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361–6.PubMedCrossRef Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361–6.PubMedCrossRef
30.
Zurück zum Zitat Pepine C, Cooper-DeHoff R. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44:509–5012.PubMedCrossRef Pepine C, Cooper-DeHoff R. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44:509–5012.PubMedCrossRef
31.
Zurück zum Zitat Hunninghake DB. Effects of celiprolol and other anti-hypertensive agents on serum lipids and lipoproteins. Am Heart J. 1991;121:696–701.PubMedCrossRef Hunninghake DB. Effects of celiprolol and other anti-hypertensive agents on serum lipids and lipoproteins. Am Heart J. 1991;121:696–701.PubMedCrossRef
32.
Zurück zum Zitat Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. Ann Intern Med. 1997;126:955–9.PubMed Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. Ann Intern Med. 1997;126:955–9.PubMed
33.
34.
Zurück zum Zitat Sharp R, Sirajuddin R, Sharief I. Impact of carvedilol on the serum lipid profile. Ann Pharmacother. 2008;42:564–71.PubMedCrossRef Sharp R, Sirajuddin R, Sharief I. Impact of carvedilol on the serum lipid profile. Ann Pharmacother. 2008;42:564–71.PubMedCrossRef
35.
Zurück zum Zitat Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292:2227–36.PubMedCrossRef Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292:2227–36.PubMedCrossRef
36.
Zurück zum Zitat Hedblad B, Wikstrand J, Janzon L, et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circ. 2001;103:1721–6. Hedblad B, Wikstrand J, Janzon L, et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circ. 2001;103:1721–6.
37.
Zurück zum Zitat Wiklund O, Hulthe J, Wistrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33:572–7.PubMedCrossRef Wiklund O, Hulthe J, Wistrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33:572–7.PubMedCrossRef
38.
Zurück zum Zitat Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93:968–73.PubMedCrossRef Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93:968–73.PubMedCrossRef
39.
Zurück zum Zitat Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–7.PubMedCrossRef Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–7.PubMedCrossRef
40.
Zurück zum Zitat Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens. 2006;8:351–6.CrossRef Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens. 2006;8:351–6.CrossRef
41.
Zurück zum Zitat Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300:902–3.PubMedCrossRef Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300:902–3.PubMedCrossRef
42.
Zurück zum Zitat Hara Y, Hamada M, Shigematsu Y, et al. Effect of beta blockers on insulin resistance in patients with dilated cardiomyopathy. Circ. 2003;67:701–4.CrossRef Hara Y, Hamada M, Shigematsu Y, et al. Effect of beta blockers on insulin resistance in patients with dilated cardiomyopathy. Circ. 2003;67:701–4.CrossRef
43.
Zurück zum Zitat Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Cardiovasc Drugs Ther. 2000;14:67–75.PubMedCrossRef Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Cardiovasc Drugs Ther. 2000;14:67–75.PubMedCrossRef
44.
Zurück zum Zitat Wikstrand J, Berglund G, Hedblad B, et al. Antiatherosclerotic effects of beta-blockers. Am J Cardiol. 2003;91:25H–9H.PubMedCrossRef Wikstrand J, Berglund G, Hedblad B, et al. Antiatherosclerotic effects of beta-blockers. Am J Cardiol. 2003;91:25H–9H.PubMedCrossRef
45.
Zurück zum Zitat Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005;18:935–42.PubMedCrossRef Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005;18:935–42.PubMedCrossRef
46.
Zurück zum Zitat Ferdinand K, Armani A. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007;6:67–71.PubMedCrossRef Ferdinand K, Armani A. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007;6:67–71.PubMedCrossRef
47.
Zurück zum Zitat Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27:2982–8.PubMedCrossRef Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27:2982–8.PubMedCrossRef
48.
Zurück zum Zitat Fogari R, Derosa G, Zoppi A, et al. Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med. 2008;47:361–6.PubMedCrossRef Fogari R, Derosa G, Zoppi A, et al. Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med. 2008;47:361–6.PubMedCrossRef
49.
Zurück zum Zitat Mason RP. A rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:489–501.PubMedCrossRef Mason RP. A rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:489–501.PubMedCrossRef
50.
Zurück zum Zitat Bellosta S, Bernin F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atherosclerosis Rep. 2000;2:76–81.CrossRef Bellosta S, Bernin F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atherosclerosis Rep. 2000;2:76–81.CrossRef
51.
Zurück zum Zitat Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA. 2004;292:2217–26.PubMedCrossRef Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA. 2004;292:2217–26.PubMedCrossRef
52.
Zurück zum Zitat Sarafidis P, McFarlane S. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diabetes Rep. 2007;7:191–9.CrossRef Sarafidis P, McFarlane S. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diabetes Rep. 2007;7:191–9.CrossRef
53.
Zurück zum Zitat Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–73.PubMedCrossRef Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–73.PubMedCrossRef
54.
Zurück zum Zitat The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme-inhibitor, ramipril, on cardiovascular events in high-risk individuals. N Engl J Med. 2000;342:145–53.CrossRef The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme-inhibitor, ramipril, on cardiovascular events in high-risk individuals. N Engl J Med. 2000;342:145–53.CrossRef
55.
Zurück zum Zitat •• Vardeny O, Uno H, Braunwald E, et al. Opposing effects of beta blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011;107:1705–09. These data from the PEACE trial show a nearly 9% increased risk of new-onset diabetes mellitus in CAD patients treated with beta-blockers. This risk was significantly attenuated if they were also treated with an ACE inhibitor. PubMedCrossRef •• Vardeny O, Uno H, Braunwald E, et al. Opposing effects of beta blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011;107:1705–09. These data from the PEACE trial show a nearly 9% increased risk of new-onset diabetes mellitus in CAD patients treated with beta-blockers. This risk was significantly attenuated if they were also treated with an ACE inhibitor. PubMedCrossRef
56.
Zurück zum Zitat Julius S, Kjedlsen SE. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–31.PubMedCrossRef Julius S, Kjedlsen SE. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–31.PubMedCrossRef
57.
Zurück zum Zitat • Rizos C, Elisaf MS, Liberopoulos EN. Are the pleotropic effects of telmisartan clinically relevant? Curr Pharn Des. 2009;15:2815–32. The authors argue that the ARB telmisartan may have additional pleiotropic effects, especially in the realm of glucose metabolism, that make this agent potentially favorable over other agents. Clinical studies, however, have yet to show definitive results confirming superiority over other ARBs. CrossRef • Rizos C, Elisaf MS, Liberopoulos EN. Are the pleotropic effects of telmisartan clinically relevant? Curr Pharn Des. 2009;15:2815–32. The authors argue that the ARB telmisartan may have additional pleiotropic effects, especially in the realm of glucose metabolism, that make this agent potentially favorable over other agents. Clinical studies, however, have yet to show definitive results confirming superiority over other ARBs. CrossRef
58.
Zurück zum Zitat Holzgreve H, Nakov R. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003;16:381–6.PubMedCrossRef Holzgreve H, Nakov R. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003;16:381–6.PubMedCrossRef
59.
Zurück zum Zitat Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med. 2008;359:2417–28.PubMedCrossRef Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med. 2008;359:2417–28.PubMedCrossRef
60.
Zurück zum Zitat Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2: overview of physiological and biochemical mechanisms. Diabetes Met. 2004;30:498–505.CrossRef Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2: overview of physiological and biochemical mechanisms. Diabetes Met. 2004;30:498–505.CrossRef
61.
Zurück zum Zitat McFarlane SI, Kumar A, Sowers JR. Mechanism by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91:30H–7H.PubMedCrossRef McFarlane SI, Kumar A, Sowers JR. Mechanism by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91:30H–7H.PubMedCrossRef
62.
Zurück zum Zitat Mancia G, Grassi G. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3–10.PubMedCrossRef Mancia G, Grassi G. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3–10.PubMedCrossRef
63.
Zurück zum Zitat Mason RP. A rational for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005;118(Suppl 12A):54–61.PubMedCrossRef Mason RP. A rational for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005;118(Suppl 12A):54–61.PubMedCrossRef
64.
Zurück zum Zitat Luscher TF, Wenzel RR, Moreau P, et al. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardioavsc Drugs Ther. 1995;9 Suppl 3:509–23.CrossRef Luscher TF, Wenzel RR, Moreau P, et al. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardioavsc Drugs Ther. 1995;9 Suppl 3:509–23.CrossRef
65.
Zurück zum Zitat Pollare T, Lithell H. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. J Hypertens. 1988;31:415–20. Pollare T, Lithell H. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. J Hypertens. 1988;31:415–20.
66.
Zurück zum Zitat • Chapman N, Chen CY, Fukita T, et al. Time to re-appraise the role of alpha- adrenoceptor antagonists in the management of hypertension. J Hypertens. 2010;28:1796–803. Data from the ASCOT trial show that the addition of a long-acting preparation of the alpha-blocker doxazosin brought about a further blood pressure lowering and a modest reduction in lipids without an increase in heart failure. The authors suggest that alpha-blockers are safe as add-on antihypertensive therapy. PubMedCrossRef • Chapman N, Chen CY, Fukita T, et al. Time to re-appraise the role of alpha- adrenoceptor antagonists in the management of hypertension. J Hypertens. 2010;28:1796–803. Data from the ASCOT trial show that the addition of a long-acting preparation of the alpha-blocker doxazosin brought about a further blood pressure lowering and a modest reduction in lipids without an increase in heart failure. The authors suggest that alpha-blockers are safe as add-on antihypertensive therapy. PubMedCrossRef
Metadaten
Titel
Lipid Effects of Antihypertensive Medications
verfasst von
Roderick Deano
Matthew Sorrentino
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 1/2012
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0214-z

Weitere Artikel der Ausgabe 1/2012

Current Atherosclerosis Reports 1/2012 Zur Ausgabe

Statin Drugs (M Clearfield, Section Editor)

Role of C-Reactive Protein When Prescribing a Statin

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.